By Paul Elias Alexander, PhD, Mark Trozzi, MD, Dan Stock, MD
Trial Site News –
Drs. Vanden Bossche and Montagnier have warned us about vaccinating during a pandemic with heavy infectious pressure and the use of very narrow spike specific (an immature, sub-optimal, incomplete, immune library spectrum) yielding, sub-optimal antibodies. That we could possibly drive vaccine-mediated viral immune escape and I argue we are seeing just that now in the UK and Israel and even in the US. “It is clear that the new variants are created by antibody-mediated selection due to the vaccination.” It is the vaccination and sub-optimal incomplete ‘unhinged and deranged’ antibody responses that is driving the emergence of the variants. Is this why so many young healthy athletes are dying?
It is now abundantly clear that the COVID-19 vaccines are ‘leaky’ (leaky vaccines do not stop infection or transmission and allows for immune escape) and do not sterilize the COVID virus (are non-neutralizing or lose this capacity very quickly). These vaccines show that the more vaccinated a nation is, the more problems they are having with the vaccine in terms of escalating infections. These vaccines do not adequately protect the upper respiratory tract. The data is clear that the vaccinated can transmit as efficiently as some who are completely unprotected. Immunity from the vaccines seem to be only about 4 to 5 months and thus how could any one think we can achieve population level herd immunity with these vaccines? It is virtually impossible that these vaccines could get us to herd immunity. Zero chance. Yet are we about to accept boosting every 5 months? Do we know if the immune system is designed for this? This, as well as antibody dependent enhancement (ADE) and antibody mediated viral enhancement (AMVE) were not studied. This was a catastrophic omission and failure by the vaccine developers and the FDA as the key regulator in enforcing this.
The Original Antigenic Sin: COVID-19 Vaccination and Sub-Optimal Initial Immune Priming Deranges the Antibody- Cytotoxic T cell Immune Response